BioAge Labs (NASDAQ:BIOA) Lowered to Strong Sell Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded BioAge Labs to “strong sell” from “sell,” although broader analyst sentiment remains “Moderate Buy,” with six buy ratings and one sell rating.
• Analysts’ consensus price target is $36.57, but individual targets vary widely from $21 to $50; the stock opened at $9.59 and has traded between $4.58 and $25.95 over the past year.
• BioAge reported a quarterly loss of $0.58 per share, better than the expected $0.65 loss, on $2.45 million in revenue. The company remains deeply unprofitable, with a negative net margin of 912.26%.

BioAge Labs (NASDAQ:BIOA - Get Free Report) was downgraded by Wall Street Zen from a "sell" rating to a "strong sell" rating in a research note issued to investors on Saturday, Wall Street Zen reports.

A number of other equities research analysts also recently weighed in on the stock. Jefferies Financial Group set a $21.00 price target on shares of BioAge Labs in a research report on Friday, July 31st. Weiss Ratings reissued a "sell (d-)" rating on shares of BioAge Labs in a research report on Tuesday, July 21st. BTIG Research restated a "buy" rating and set a $40.00 price objective on shares of BioAge Labs in a research note on Monday, August 3rd. Roth Capital reaffirmed a "buy" rating and issued a $25.00 price objective on shares of BioAge Labs in a report on Friday, July 31st. Finally, Needham & Company LLC cut their target price on BioAge Labs from $50.00 to $35.00 and set a "buy" rating for the company in a research report on Friday, July 31st. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, BioAge Labs currently has an average rating of "Moderate Buy" and a consensus price target of $36.57.

BioAge Labs Stock Performance

BIOA stock opened at $9.59 on Friday. The company's 50-day simple moving average is $16.50 and its 200 day simple moving average is $17.82. BioAge Labs has a 52 week low of $4.58 and a 52 week high of $25.95. The company has a market capitalization of $440.18 million, a PE ratio of -4.03 and a beta of 0.94.

BioAge Labs (NASDAQ:BIOA - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.58) EPS for the quarter, topping analysts' consensus estimates of ($0.65) by $0.07. The business had revenue of $2.45 million for the quarter. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. On average, analysts forecast that BioAge Labs will post -2.45 EPS for the current year.

Institutional Investors Weigh In On BioAge Labs

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of BioAge Labs in the 2nd quarter valued at $69,831,000. Jupiter Topco LLC acquired a new position in shares of BioAge Labs during the 2nd quarter worth $52,597,000. Janus Henderson Group PLC lifted its position in shares of BioAge Labs by 411.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company's stock worth $36,597,000 after buying an additional 1,685,063 shares during the last quarter. Octagon Capital Advisors LP boosted its stake in BioAge Labs by 9.4% in the first quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company's stock valued at $30,573,000 after buying an additional 150,000 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in BioAge Labs by 6.0% in the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company's stock valued at $9,709,000 after buying an additional 93,694 shares in the last quarter.

About BioAge Labs

BioAge Labs NASDAQ: BIOA is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source